Flagship Pioneering Special Opportunities Fund II, L.P.

Flagship Pioneering Special Opportunities Fund II, L.P. insider trades: Generate Biomedicines (GENB) stock purchases

Generate Biomedicines Last trade Mar 2, 2026 8 Form 4 filings
$0
Sold, last 12 months
0 sales
$75.0M
Bought, last 12 months
3 buys
7
Open-market trades
since 2020
4
Companies
last trade 2026

Trades on the price chart

Daily close, with an arrow on each day they bought or sold

Companies

Where Flagship Pioneering Special Opportunities Fund II, L.P. reports to the SEC

Open-market buys and sales

7 trades reported on SEC Form 4, newest first

DateStockTypeValue
Mar 2, 2026GENB↑ Buy$25.0M
Mar 2, 2026GENB↑ Buy$25.0M
Mar 2, 2026GENB↑ Buy$25.0M
Feb 27, 2023OMGA↑ Buy$11.5M
Feb 27, 2023OMGA↑ Buy$7.7M
Aug 3, 2021OMGA↑ Buy$20.0M
Oct 27, 2020FHTX↑ Buy$2.4M

Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.

Other GENB insiders

Open-market trades in the last 12 months

About Flagship Pioneering Special Opportunities Fund II, L.P.'s insider trades

Flagship Pioneering Special Opportunities Fund II, L.P. is an insider at Generate Biomedicines (GENB). Since Oct 27, 2020, it has reported 7 open-market purchases worth $116.6M and no sales on SEC Form 4. In the last 12 months: 3 buys ($75.0M).

Its filings also include conversions (4 filings), grants and awards (2 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.

How to read insider trades

Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every GENB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.